Drug Profile
Cannabidiol inhalation - TFF Pharmaceuticals
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator TFF Pharmaceuticals
- Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Resorcinols; Skin disorder therapies; Sleep disorder therapies; Small molecules
- Mechanism of Action Cannabinoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Research Unspecified
Most Recent Events
- 18 May 2020 Chemical structure information added
- 15 Apr 2020 TFF Pharmaceuticals in-licenses Thin Film Freezing (TFF) technology from University of Texas at Austin
- 06 Apr 2020 Cannabinoid based therapeutics is available for licensing as of 06 Apr 2020. www.tffpharma.com